Abstract Library

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,

#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study

Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,

Keywords: carcinoid syndrome, 5-HIAA, telotristat,

#1809 What Do We Know About Carcinoid Heart Disease? A Systematic Literature Review

Introduction: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ovcinnikova O

Authors: Ovcinnikova O, Marshall M, Bagnati F, Hoffmanns P, Taveau ,

Keywords: carcinoid heart disease, systematic literature review, outcomes,

#1806 Epidemiology of Carcinoid Heart Disease (CHD) in Patients (pts) with Carcinoid Syndrome (CS): A Systematic Literature Review

Introduction: CHD develops in the context of CS due to the exposure of high levels of vasoactive substances, such as serotonin.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ovcinnikova O

Authors: Ovcinnikova O, Marshall M, Bagnati F, Hoffmanns P, Taveau C,

Keywords: carcinoid syndrome, heart disease, epidemiology, prevalence, mortality,

#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hoffmann J, Corbett L, Detjen K, Thedieck K, Sers C,

Keywords: pancreatic neuroendocrine tumors, MAPK pathway,